Eli Lilly to Acquire Calytrix Bio in Deal Valued Up to $1.5 Billion

Pharmaceutical giant Eli Lilly (LLY) has entered into an agreement to acquire Calytrix Bio, a privately held biotechnology company specializing in treatments for rare blood disorders. The transaction is structured with an unspecified upfront payment and potential milestone payments that could bring the total deal value to $1.5 billion. The acquisition aligns with Eli Lilly's strategy to expand its specialized medicine portfolio. By integrating Calytrix Bio's research and development capabilities, Lilly aims to strengthen its position in the rare disease market, specifically targeting hematological conditions.

2 articles from 1 source · updated

Coverage